ESMO 2022 | Tumor characteristics of patients with recurrence after neoadjuvant ipi + nivo in melanoma

Name: Tumor characteristics of patients with recurrence after neoadjuvant ipi + nivo in melanoma
Uploaded: 2022-09-10T00:00:00Z
Duration: 2 min 43 s
Description: Judith Versluis, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses clinical features of acquired resistance in stage IV melanoma patients treated with immune checkpoint inhibition. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Judith Versluis • 10 Sep 2022

ESMO 2022

Melanoma Skin Cancer Ipilimumab Nivolumab

Judith Versluis, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses clinical features of acquired resistance in stage IV melanoma patients treated with immune checkpoint inhibition. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.